A Phase 4 interventional study of Percutaneous needle fasciotomy and Corticosteroid injection in Dupuytren Contracture, Dupuytren's Disease and Contracture, sponsored by Regionshospitalet Silkeborg. Recruiting at 1 site in Denmark. Open to participants aged 45 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-05-17.
Sponsored by Regionshospitalet Silkeborg · Phase 4, Interventional, and Treatment
Comparing percutaneous needle fasciotomy +/- corticosteroid injection for Dupuytren's contracture affecting metacarpophalangeal joints. A clinician-initiated, multicenter, randomized controlled trial.
78 studies on the registry are indexed under Dupuytren Contracture; 18 are open to participants now.
This study's planned enrollment of 400 is above the median of 72 across 57 interventional studies indexed under Dupuytren Contracture.
Browse Dupuytren Contracture studies →Regionshospitalet Silkeborg is the lead sponsor of 10 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Sufficient correction of metacarpophalangeal (MCP) joint during the PNF treatment, defined as \<20° passive extension deficit (PED), is a prerequisite for inclusion.
Inclusion Criteria:
Exclusion Criteria:
Percutaneous needle fasciotomy with corticosteroid injection
Procedure: Percutaneous needle fasciotomy · Drug: Corticosteroid injection
Percutaneous needle fasciotomy with saline injection
Procedure: Percutaneous needle fasciotomy · Other: Saline injection
Percutaneous needle fasciotomy ad modum Lermusiaux and Debeyre
Depo-Medrol
Isotonic saline
Recurrence rate
Recurrence is defined as 20 degrees or more passive extension deficit in metacarpophalangeal joint from baseline
Time frame: 2 years
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Regionshospitalet Silkeborg